MOTS-c research: a mitochondrial-derived peptide, in plain English
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome. The studies in our register are in mice and in cells. It is prohibited in sport.
- Evidence grade or review status for every compound
- Sources listed on every page
- US and sport status, dated
Compounds studied in this area
Grades describe the published evidence, not a promise of any effect.
What has been studied
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. The 2015 study that described it was done in mice with diet-induced obesity and insulin resistance. [1]
What the research does not show
Saying what we don't know is part of the evidence.
Any effect of MOTS-c in people: one placebo-controlled phase 2 trial is registered and recruiting, and no trial giving MOTS-c to people has published results.
Anything about sport performance in people. MOTS-c is prohibited in sport.
Where it stands legally
As of November 2026. See the full tracker and the changelog.
| Compound | FDA approval | 503A compounding (2026) | WADA (2026 List) |
|---|---|---|---|
| MOTS-c | Not approved | FDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yet | Prohibited (S4.4.1, named) |
Worth knowing
Research use only
None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.
What research use only meansNo doses, ever
We publish no doses, protocols, or cycles for people, on any page.
Why we publish no dosesHow we grade evidence
Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.
Evidence gradesQuestions people ask
Is MOTS-c allowed in sport?
No. WADA's Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, in both the 2026 and 2027 lists. It is prohibited at all times.
Has MOTS-c been tested in people?
A placebo-controlled phase 2 trial is registered and recruiting, and no trial giving MOTS-c to people has published results. Other human studies measured the body's own MOTS-c levels, not what happens when it is given. We make no statement about effects in people.
Sources
- Lee C, et al. [Cell and mouse study of MOTS-c, a peptide encoded in mitochondrial DNA.] Cell Metab. 2015;21(3):443–454. PMID 25738459. doi.org/10.1016/j.cmet.2015.02.009
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
- U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- ClinicalTrials.gov. NCT07505745: placebo-controlled phase 2 trial of MOTS-c in adults with prediabetes and overweight or obesity (recruiting; no results). clinicaltrials.gov/study/NCT07505745
Related pages
Start with the evidence
Every page sourced and dated, including what the research does not show.
Open the research library